1. Home
  2. |Insights
  3. |GAO Stands Down in Lengthy Dispute with VA Over Set-Asides

GAO Stands Down in Lengthy Dispute with VA Over Set-Asides

Client Alert | less than 1 min read | 12.26.12

In Kingdomware Techs.--Recon., GAO put the Veteran Owned and Service Disabled Veteran Owned Small Business community on notice that it will no longer hear protests alleging that VA violated the Veterans Benefits Act of 2006 by using the Federal Supply Schedule without first determining whether a set aside was appropriate for them because protesters "will be unable to obtain meaningful relief" from GAO. The decision followed over a year of the VA defying numerous GAO recommendations on this very issue and a Court of Federal Claims decision by Judge Firestone in December favoring the agency's interpretation.


Contacts

Insights

Client Alert | 7 min read | 09.14.26

AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development

Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage. ...

View All Insights